GVR Report cover Vaccine Adjuvants Market Size And Forecast By Type (Pathogen, Adjuvant Emulsion, Particulate), By Route of Administration (Oral, Intradermal, Intranasal, Intramuscular), By Application, And Trend Report

Vaccine Adjuvants Market Size And Forecast By Type (Pathogen, Adjuvant Emulsion, Particulate), By Route of Administration (Oral, Intradermal, Intranasal, Intramuscular), By Application, And Trend Analysis, 2018 - 2025

  • Report ID: GVR-1-68038-612-7
  • Number of Pages: 90
  • Format: Electronic (PDF)

Industry Insights

The global vaccine adjuvants market size was valued at USD 308.99 million in 2016 and is anticipated to grow with a CAGR of 10.6%. Rising prevalence of cervical cancer, infectious diseases such as Human Papillomavirus (HPV), HIV, tuberculosis, etc., and other fatal diseases are expected to boost the demand for adjuvants.

Besides, growing focus on the long-lasting effect of immunization against existing and emerging diseases is expected to boost demand for adjuvants. The importance of adjuvant research for the development of these products has increased significantly due to the inadequate immunogenicity of innovative vaccine antigens. Moreover, the increasing use of recombinant and synthetic vaccines is expected to accelerate the growth of this market in the coming years.

U.S. vaccine adjuvants market

Major players are engaged in the discovery and development of new adjuvants to treat fatal diseases. Products under clinical trials include AS01, ISCOM & ISCOMMATRIX, and AS02, and the presence of these pipeline drugs is estimated to further boost the market.

The U.S. is a developed country with a huge population and a large number of travelers visit the country, which increases the need for immunization for the safety of the local population. Also, a rise in favorable government initiatives for immunization of people against serious diseases is anticipated to boost the market. For instance, the National Institute of Allergy and Infectious Diseases initiated a program for advancements in adjuvants for human use.

Type Insights

Based on type, the vaccine adjuvants market is segmented into a pathogen, adjuvant emulsion, particulate, combination, and others. Among these, the particulate type held the largest market share in 2016, followed by adjuvant emulsion. This large share can be attributed to the presence of a wide range of products and greater efficiency against the diseases.

Particulate type includes adjuvants consisting of alum, virosomes, and cytokines. Alum is the most commonly used adjuvant consisting of aluminum salts. It is used in hepatitis B and HPV vaccines. Virosomes that are particles resembling noninfectious viruses are used as adjuvants in hepatitis A, Epaxal, and influenza vaccine Inflexal.

On the other hand, the pathogen type segment is expected to be the fastest-growing over the forecast period. Some pathogenic adjuvants tested include monophosphoryl lipid A. It is combined with alum to produce AS04 adjuvant used in an HPV-Cervarix.

Application Insights

Infectious diseases accounted for the largest share in the vaccine adjuvants market. This large share can be attributed to the gradually growing prevalence of infectious diseases, such as malaria, influenza, hepatitis A, B, & C, and others. Also, the presence of strong pipeline products for vaccine adjuvants related to infectious diseases is anticipated to fuel the market growth in the coming years. This includes CpG (TLR 9 agonist) vaccine adjuvant from InvivoGen. The product is in phase 3 of clinical trial and provides CD8 T cell-mediated immunity and Th1-type immunity.

Cancer is identified to be the fastest-growing application segment due to its high prevalence and ongoing R&D for targeted therapy for various types of cancers. Moreover, increasing the use of adjuvants, such as Cervarix, is further anticipated to fuel growth.

Administration Type Insights

Based on the route of administration, adjuvants are categorized into oral, intradermal, intranasal, intramuscular, and others. The intramuscular segment accounted for the largest market share in 2016 due to better immune specificity. These include vaccines for HPV, influenza, meningitis, etc. The efficacy of vaccines depends on the route of administration. For instance, alum salts, which are the most widely used parenteral adjuvants, are ineffective when administered by the oral or nasal route.

On the other hand, the intradermal route is expected to be the fastest-growing segment due to longer absorption time and duration of action as compared to other routes, which increases the demand for vaccines administered through this route. Some adjuvants, such as TLR3-Ligand Poly (I:C), induce mucosal antibody responses and protect against genital HSV-2 infection when administered intradermally.

Global vaccine adjuvants market

Regional Insights

North America held the largest market share in 2016 followed by Europe. The factors contributing to the growth of the vaccine adjuvants market in the North American region are a rise in investments for R&D of new therapeutics and an increase in fatal epidemic diseases. Thus, leading to the need for immunization against acute and chronic diseases. Also, the local presence of key market players in the U.S. increases the penetration of products. For instance, Adjuvance Technologies, Inc. has developed a portfolio of adjuvants targeted toward the treatment of various diseases.

Asia Pacific was estimated to be the fastest-growing market due to the continuously improving healthcare facilities, including the availability of medicines, coupled with rising R&D funding to meet the huge unmet demands. This is expected to increase the revenue share over the forecast period.

Competitive Insights

Some of the key participants in the market are GlaxoSmithKline plc.; Novavax, Inc.; Adjuvance Technologies, Inc.; SPI Pharma.; Agenus, Inc.; CSL Limited; InvivoGen; and Brenntag Biosector.

These market players are focusing on expanding their businesses in developing regions to increase their market share. Furthermore, they are adopting strategies such as collaborations, mergers & acquisitions, and new product development. For instance, in July 2017, GSK collaborated with Exscientia to develop new drugs.

Report Scope



The base year for estimation


Actual estimates/Historical data

2014 - 2016

Forecast period

2017 - 2025

Market representation

Revenue in USD Million & CAGR from 2016 to 2025

Regional scope

North America, Europe, Asia Pacific, Latin America, & MEA

Country scope

U.S., Canada, UK, Germany, Japan, China, Brazil, South Africa

Report coverage

Revenue forecast, company share, competitive landscape, growth factors, and trends

15% free customization scope (equivalent to 5 analyst working days)

If you need specific market information, which is not currently within the scope of the report, we will provide it to you as a part of customization

Segments Covered in the Report

This report forecasts revenue growth and provides an analysis of the industry trends in each of the sub-segments from 2014 to 2025. For this study, Grand View Research, Inc. has segmented the vaccine adjuvants market based on type, application, route of administration, and region: 

  • Product Type Outlook (Revenue, USD Million; 2014 - 2025)

    • Pathogen

    • Adjuvant Emulsion

    • Particulate

    • Combination

    • Others

  • Application Outlook (Revenue, USD Million; 2014 - 2025)

    • Infectious Disease

    • Cancer

    • Others

  • Administration Type Outlook (Revenue, USD Million; 2014 - 2025)

    • Oral

    • Intradermal

    • Intranasal

    • Intramuscular

    • Others

  • Regional Outlook (Revenue, USD Million; 2014 - 2025)

    • North America

      • The U.S.

      • Canada

    • Europe

      • Germany

      • UK

    • Asia Pacific

      • China

      • Japan

    • Latin America

      • Brazil

    • MEA

      • South Africa

gvr icn


gvr icn

This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.

gvr icn


We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.

Contact us now to get our best pricing.

esomar icon

ESOMAR certified & member

D&B icon

Leading SME award by D&B

We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.

great place to work icon